Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients

Table 5 Multivariate analysis by the Cox proportional hazard regression model for OS in GBM patients from tumor banks

Variable	HR (95% CI)	P
Age (years)
≥ 60 vs < 60	NA	0.117
LANCL2 gene status
Amplification vs no alteration	2.319 (1.306–4.115)	0.004
EGFR gene status
Amplification vs no alteration	NA	0.605
LANCL2 and EGFR genes status
Co-amplification vs no alteration	NA	0.656

ISSN: 1479-5876